Double Point Ventures LLC / Lumos Pharma, Inc.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.